JAMA Network
About the Study: In this randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer, stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT for disease-free survival at 3 years. SBRT was associated with better bowel-related quality of life, but cancer control was not improved.
Reporting Resource:
Visit JAMA+ Trials for JAMA Network highlights curated by Editor in Chief Alison Huang, MD, MAS. Dive into Dr Huang's " Theme of the Month ," stay up to date with our resources page , and search recently published trials by topic .
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
